GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Hangzhou Tigermed Consulting Co Ltd (SZSE:300347) » Definitions » Equity-to-Asset

Hangzhou Tigermed Consulting Co (SZSE:300347) Equity-to-Asset

: 0.71 (As of Dec. 2023)
View and export this data going back to 2012. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Hangzhou Tigermed Consulting Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ¥21,027 Mil. Hangzhou Tigermed Consulting Co's Total Assets for the quarter that ended in Dec. 2023 was ¥29,681 Mil. Therefore, Hangzhou Tigermed Consulting Co's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.71.

The historical rank and industry rank for Hangzhou Tigermed Consulting Co's Equity-to-Asset or its related term are showing as below:

SZSE:300347' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.56   Med: 0.69   Max: 0.83
Current: 0.71

During the past 13 years, the highest Equity to Asset Ratio of Hangzhou Tigermed Consulting Co was 0.83. The lowest was 0.56. And the median was 0.69.

SZSE:300347's Equity-to-Asset is ranked better than
64.02% of 239 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.59 vs SZSE:300347: 0.71

Hangzhou Tigermed Consulting Co Equity-to-Asset Historical Data

The historical data trend for Hangzhou Tigermed Consulting Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Array ( [0] => - [1] => - [2] => - [3] => - [4] => - [5] => 0.56 [6] => 0.83 [7] => 0.76 [8] => 0.71 [9] => 0.71 )
Hangzhou Tigermed Consulting Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.83 0.76 0.71 0.71

Hangzhou Tigermed Consulting Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.71 0.72 0.69 0.70 0.71

Competitive Comparison

For the Diagnostics & Research subindustry, Hangzhou Tigermed Consulting Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hangzhou Tigermed Consulting Co Equity-to-Asset Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Hangzhou Tigermed Consulting Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Hangzhou Tigermed Consulting Co's Equity-to-Asset falls into.



Hangzhou Tigermed Consulting Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Hangzhou Tigermed Consulting Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=21026.775/29680.742
=0.71

Hangzhou Tigermed Consulting Co's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=21026.775/29680.742
=0.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hangzhou Tigermed Consulting Co  (SZSE:300347) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Hangzhou Tigermed Consulting Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Hangzhou Tigermed Consulting Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Hangzhou Tigermed Consulting Co (SZSE:300347) Business Description

Traded in Other Exchanges
Address
Block 8, No. 19 Jugong Road, Room 2001-2010, 20th Floor, Xixing Sub-District, Binjiang District, Hangzhou, CHN, 310053
Hangzhou Tigermed Consulting Co Ltd is a China-based Contract Research Organization. The company's segment includes Clinical trial solutions and Clinical-related and laboratory services. It generates maximum revenue from the Clinical trial solutions segment. The company's offered services include bioanalytical, medical writing, biostatistics analysis, and medical imaging. The therapeutic areas of the company include Infections, Hematology, Cardiovascular, Endocrinology, Rheumatology, Nephrology, and Central Nervous System (CNS) among others.

Hangzhou Tigermed Consulting Co (SZSE:300347) Headlines

No Headlines